Using a wearable ring to spot worsening heart failure early
Studies whether a wearable ring can detect worsening heart failure in adults.
Plain-language title generated from the registry record
Registry title: Observational Study Designed to Detect Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device
Key facts
- Where
- Tampa, United StatesSee the 2 sites
Where in United States
- USFTampa, United StatesTaking people
- USF Office of Clinical ResearchTampa, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CHFDX,Inc.
- Trial code
- NCT07350759
- Record updated
- 11 March 2026
- Original description
This is a prospective, observational pilot study designed to develop a mathematical algorithm capable of predicting decompensation of congestive heart failure (dCHF) using physiologic data collected from a non-invasive wearable device. Participants with a remote hemodynamic pulmonary artery pressure monitor will wear a wearable device continuously for up to 12 months. Wearable data will be analyzed in relation to the hemodynamic monitor defined sentinel events of heart failure decompensation to identify predictive signal patterns. Optional biospecimen (DNA, blood, urine) and voice sample collection will support future biomarker discovery.Read full original descriptionShow less
An Observational Study to Develop an Algorithm to Predict Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device.
This is a prospective, observational pilot study designed to develop a mathematical algorithm capable of predicting decompensation of congestive heart failure (dCHF) using physiologic data collected from a non-invasive wearable device. Participants with a remote hemodynamic pulmonary artery pressure monitor will wear a wearable device continuously for up to 12 months. Wearable data will be analyzed in relation to the hemodynamic monitor defined sentinel events of heart failure decompensation to identify predictive signal patterns. Optional biospecimen (DNA, blood, urine) and voice sample collection will support future biomarker discovery.
Inclusion: • Age ≥ 18 years; Current use of a hemodynamic sensoring device; At least 4 consecutive weeks of stabilized "goal" pulmonary artery pressures; Access to a personal smartphone with Wi-Fi or cellular connectivity.
Exclusion: • Inability to provide informed consent; Inability to read or understand English; Likely non-adherence to wearable device use; Prisoners; Pregnant females.